-
Cannabinoid Drug For Agitation In Alzheimer's Yields Cognitive Improvements In Clinical Trial
Tuesday, November 26, 2024 - 11:12am | 667IGC Pharma, Inc.(NYSE:IGC) reported additional interim data from its ongoing Phase 2 clinical trial evaluating IGC-AD1 for agitation in dementia associated with Alzheimer's disease. IGC-AD1 targets neuro-inflammation and CB1 receptor dysfunction,. The investigational drug contains THC as one of two...